Correction updates affiliation in CAPRV2023 qPCR surveillance paper

A new correction in Frontiers in Veterinary Science doesn’t alter the science behind a recently published CAPRV2023 diagnostic paper, but it does amend the formal record. Published May 11, 2026, the notice corrects the first author affiliation on a July 31, 2025, study that described one-step and two-step qPCR assays for full-cycle epidemiological surveillance of CAPRV2023 in golden pompano. The change adds “Fisheries College of Guangdong Ocean University” to the affiliation, and the journal says the original article has been updated. (frontiersin.org)

The underlying study arrived amid growing concern about CAPRV2023, also referred to as carpione rhabdovirus strain 2023, which researchers have linked to substantial mortality in farmed golden pompano in China. Earlier reporting in Aquaculture described CAPRV2023 as a newly identified rhabdovirus associated with mass mortality in the species, helping establish the pathogen as an emerging threat in marine fish production. That backdrop helps explain why the 2025 Frontiers paper focused on assay development, validation, and surveillance across a full farming cycle rather than a narrower lab-only proof of concept. (sciencedirect.com)

In the original research, investigators developed two TaqMan probe-based assays targeting the viral G protein gene. The two-step qPCR assay reached a reported detection limit of 2 copies/μL, while the one-step assay reached 15 copies/μL. Both showed no cross-reactivity with a panel of other aquatic pathogens tested by the authors, and both outperformed conventional PCR in clinical and environmental samples. The study also positioned the one-step format as more practical for field use because it combines reverse transcription and amplification in a closed-tube workflow, reducing handling steps and potential contamination risk. (frontiersin.org)

The surveillance component is what makes the paper especially relevant for animal health monitoring. The team analyzed samples from 87 golden pompano culture cages across central and western Guangdong, eastern Guangxi, and Hainan between June 2024 and January 2025. According to the paper, qPCR-positive rates in water and tissue samples were 77.63% and 66.2%, respectively, versus 19.4% and 41.4% with conventional PCR. The authors also reported that viral loads were highest in spleen and liver, and that ultrafiltration-supported testing of water samples could support early warning efforts. (frontiersin.org)

There doesn’t appear to be outside reaction specifically to the correction itself, which is unsurprising given its narrow scope. But the broader diagnostic push around CAPRV2023 is clearly continuing. Separate 2025 and 2026 papers indexed in search results describe additional assay development work for CAPRV2023 detection, including rapid food-product testing and a one-step TaqMan approach aimed at surveillance under conditions of viral target drift. Taken together, that suggests the field sees CAPRV2023 diagnostics as an active area of method refinement rather than a settled problem. (mdpi.com)

Why it matters: For veterinary professionals working in aquaculture, corrections like this are easy to dismiss, but they serve an important record-keeping role. This notice does not undermine the reported assay performance, so laboratories, fish health specialists, and epidemiology teams can continue to view the study as part of the emerging evidence base for CAPRV2023 surveillance. More broadly, the paper reflects a familiar shift in aquatic animal health: from diagnosing outbreaks after mortality spikes to building surveillance systems that use more sensitive molecular tools, including environmental sampling, to detect circulation earlier. (frontiersin.org)

For clinicians and diagnosticians outside aquaculture, the story is also a reminder that “correction” headlines don’t all mean the same thing. Some corrections change interpretation; this one appears limited to institutional attribution. In practical terms, that means the action item is mostly bibliographic: use the corrected version when citing the paper, and keep an eye on how these assays are validated, standardized, and potentially adopted in routine fish disease surveillance programs. (frontiersin.org)

What to watch: The next developments to watch are independent validation, uptake in regional surveillance programs, and whether CAPRV2023 testing moves toward more standardized field-deployable workflows for water and tissue screening across commercial golden pompano production. (frontiersin.org)